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A B S T R A C T
The theory of breast cancer as a child deficiency disease is an inversion of the current paradigm, which considers full-
term pregnancies to be a protective factor and uses nulliparous women as the reference group. Instead, the
theory of breast cancer as a child deficiency disease says that women with the highest parity (about 20, which is
the limit of human fertility) are those with the lowest risk and should be used as the reference group in risk
estimations. This theory is explained biologically by converting parity from the simple value of number of
children into an understanding of the long-lasting biological and immunological effects of pregnancy. These
effects can be reflected, as measured by functional genomics, in gene expression of the immune cells in the
blood. Each pregnancy represents a unique fetus or semi-allograft, which provokes the creation and deposit of
memory cell clones in the mother. Gene expression levels have been found to change linearly with number of
full-term pregnancies in healthy women, but not in breast cancer patients. High hormone levels are necessary for a
successful pregnancy, as they modulate the immune response from adaptive to innate in order to protect the
fetus (considered as a semi-allograft) from rejection. At the end of the pregnancy, hormone levels drop, and the
immune system recognizes the semi-allograft, but not in time for rejection to occur before birth. High hormones
levels are also classified as carcinogens illustrating that carcinogenesis in the breast could be viewed as a war or
balance between later exposures to hormonal carcinogens and the protection of the immune system. We propose
that breast tumors are pseudo semi-allografts made up of transformed breast tissue cells. Assuming that the
sensitivity to the exposure to increased levels of endogenous or exogenous hormones in women with breast
cancer mimic those that occur in pregnancy, these breast tumor cells are protected against the body’s immune
reaction, just as the fetus is during pregnancy. However, with more pregnancies, the potential to eradicate the
pseudo semi-allograft might increase due to enhanced immune surveillance. The theory of breast cancer as a
child deficiency disease proposes that the protective effect of pregnancy on breast cancer incidence via the
immune system is independent of other risk factors.
The theory
The theory of breast cancer as a child deficiency disease proposes that
breast cancer is the result of immune deficiency in low-parity women
combined with a dual effect of hormone levels. Moreover, the theory
considers breast cancer as a pseudo semi-allograft.
Background
Despite many decades of research, there is still no general or
consistent theory of breast cancer. Nor is there any unifying concept
that explains the mechanism of pregnancy-related breast cancer pro-
tection. However, there are some main theories, such as decreased
number of mammary stem cells; increased differentiation of breast
epithelial cells; and increased estrogen responsiveness [1]. Most of
these theories focus on local changes in the mammary gland.
Most studies on parity and breast cancer have been conducted in
low-parity countries like Western Europe, including Norway, or the US.
In international consortia, like the European Prospective Investigation
into Cancer and Nutrition (EPIC) [2] and the Oxford Collaborative
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Group on Breast Cancer [3], the average number of children per woman
is 2–3. Moreover, nulliparous women have been traditionally selected
as the reference group, and have been compared with the so-called
high-parity group (4+ or 5+ children). These studies are limited in
their capacity to explain breast cancer incidence, since the major pro-
tective factor, parity, is not measured to its full extent.
In the absence of a coherent theory, a wide variety of risk factors has
been explored [4]. Body mass index has been revealed to be a weak risk
(caption on next page)
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factor, with an effect that can be related to an increased production of
estrogens in fat tissue. Other factors include genetic factors, which are
independent of other risk factors. Diet has also been investigated
heavily over the last 30 years, but findings have been mostly negative
[5,6], save those for alcohol consumption. Smoking might be a risk
factor in young women, and radiation is also a risk factor for breast
cancer. The complicated and dynamic changes in hormone levels re-
lated to menopausal status and pregnancies are illustrated in Figure 1.
Combined exogenous hormones like oral contraceptives and hor-
mone replacement therapy have also been classified as human carci-
nogens [7]. Estrogens alone are weak carcinogens, while gestagens
alone might increase the risk of specific subtypes of receptor-positive
breast cancer [8]. Large nested case-control studies, like those carried
out in the EPIC cohort [2], have shown that increased plasma or serum
concentrations of almost all female hormones are related to an in-
creased risk of breast cancer. The relative risk estimates of high versus
low concentrations (measured in tertiles) could be in the order of
two–three among postmenopausal women. Interestingly, there was no
evidence of a relationship between levels of the same hormones and
number of children, indicating that, as a risk factor for breast cancer,
hormone levels are independent of parity [9].
Endogenous hormones act as breast carcinogens throughout a wo-
man’s life. In this respect, both early menarche and late menopause
increase the risk of breast cancer, early age at first full-term pregnancy
decreases the risk, and older age at first full-term pregnancy increases
the risk. Furthermore, it has been shown that abortions have no pro-
tective effect on breast cancer [10].
The immune system and hormones during pregnancy
Since pregnancy is unequivocally the most common alloimmuni-
zation event in humans [11], multiparous women likely have higher
gene expression levels than nulliparous women. Fetal antigens can be
found in maternal tissue many years after pregnancy [12,13]. The
woman’s immune status changes during pregnancy, during which fetal
antigens are presented to maternal major histocompatibility complex in
secondary lymphoid organs, indicating a systematic priming of the
mother to indirect allo-recognition. [14]. Although data on primed T
cells in maternal tissue are mainly derived from animal experiments it
has been shown that primed human T cells can be hyporesponsive, with
limited capacity for proliferation and cytokine production [15].
Background evidence for the theory: Epidemiology
The original observation in favor of the theory of breast cancer as a
child deficiency disease, which is an inversion of the parity-breast
cancer paradigm, was the lack of cohort and age-specific mortality rate
change in Norway based on corresponding figures from 1951 to 85.
Indeed, during this period there were no changes in breast cancer
treatment [16], but parity changed dramatically from the end of the
19th century to the end of the Second World War. This led to stable age-
specific breast cancer mortality and birth cohort-cumulated breast
cancer mortality rates. No association was observed between these
changes in parity and breast cancer mortality when the range of ex-
posure was defined as a parity of 0, 1, 2, 3, or 4+. However, if the
maximum parity was changed to around 20, and that maximum was
used as the reference group, considering a parity of 0 as high risk, the
change (20–4=16) would be only 1/5 of the exposure range. These
relatively small changes were not expected to affect mortality rates in
an association analysis.
To test the theory of breast cancer as a child deficiency disease,
information on parity and age at first full-term pregnancy from the
1970 Census were linked to the register of death certificates in Statistics
Norway [17]. In the 1970 census, Norwegian women were interviewed
at home by trained interviewers. Using women with 8–9 children as the
unexposed (to lack of childbirths) reference group, the relative risk for
nulliparous women was 4.6 (95% CI; 2.3–7.9) and the relative risk for
uniparous women was around 3.8–4.5, with a population attributable
risk of 72% due to low parity. The analysis showed that for high-parity
women, age at first and last birth did not matter. There was evidence
for a further decrease in RRs among women with 10–11 children, but
this could only be calculated for women aged 65–74 years at the start of
follow-up, due to the lack of high parity in younger age groups.
The next step was to test the theory in a nationally representative
study. The Norwegian Women and Cancer (NOWAC) study was chosen
for this. Women were recruited into the NOWAC study between 1991
and 2007 [18]. The last update included 6536 incident cases of breast
cancer. In a linear additive model, the decrease in breast cancer in-
cidence was 8% per child. We found the same absolute difference be-
tween nulliparous and uniparous women as between women with five
or six children, in agreement with an additive model effect. The effect
of pregnancy was independent of all established risk factors in stratified
analyses. Tests for heterogeneity between strata were not significant
except for a borderline significance of history of breast cancer in the
mother (p= 0.06). Regarding exogenous hormones, use of hormone
replacement therapy increased the incidence levels, but did not change
the protecting effect conferred by each full-term pregnancy. Oral con-
traceptives had no long-term effects. Advanced age at first full-term
pregnancy had the same effect as one full-term pregnancy, and lactation
showed no interaction with parity. Increased body mass index showed
no effect, but the NOWAC study contains few very obese persons.
Women with six children had an adjusted, multivariate relative risk of
0.49 (Cox regression). There were too few women in the cohort for
further analyses beyond 6 children.
Adding novel results from integrated systems epidemiology
analyses
We proposed the term of systems epidemiology in 2008 as a new
scientific discipline [19] aimed at understanding the carcinogenic
process through the incorporation of functional genomics into the
prospective design. To carry through this idea, within the NOWAC
study of 172 000 Norwegian women, we created a postgenome biobank,
which contains blood samples buffered for conservation of mRNA from
Fig. 1. Illustration of the complicated interactions between the immune system and hormone levels that occur during each pregnancy are given panels A–D. Red lines
indicate increased risk, green lines indicate support for the pregnancy, yellow lines the immune surveillance. A) Before first pregnancy, premenopausal: -endogenous
and exogenous hormones act as carcinogens. B) During pregnancy: -the pregnancy and the immune shift depend on high levels of endogenous hormones. -the pseudo
semi-allograft (fetus) is protected from rejection through these hormonal effects. -each pregnancy changes the overall immune reaction to increased innate and
reduced adaptive responses. -each fetus or pseudo semi-allograft differs from the next. C) At the end of the pregnancy and birth: -hormone levels drop abruptly.
-decreasing levels of hormones increase the immune reaction to increased adaptive and reduced innate responses. -the immune system recognizes the pseudo semi-
allograft, starting a rejection process. -the child is born before the immune system would be able to harm the pseudo semi-allograft by rejection mechanisms. -during
this late phase, the immune response produces memory cell clones directed against fetus-derived antigens, giving the mother lifelong immunity against these
antigens. -these procedures are repeated for each full-term pregnancy, not in abortions. D) Postmenopausal: -high-parity women will have more memory cell clones
to raise specific immune responses against overlapping epitopes from former fetuses and cancer-associated antigens expressed in novel neoplastic cells – the clone
war. -use of exogenous hormones like hormone replacement therapy might shift the immune system in a manner that mimics changes that occur during pregnancy,
resulting in reduced adaptive responses and enhanced susceptibility to breast cancer. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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50 000 NOWAC participants selected randomly [20]. The addition of
functional genomic analyses in both the blood and tissue of breast
cancer patients and healthy controls have shown the potential of
functional analyses [21,22]. Each woman has answered from two to
four questionnaires about lifestyle, with a focus on exposures to en-
dogenous and exogenous hormones, fertility, and diet.
Our term integrated systems epidemiology approach combines the
standard epidemiological analysis with functional analyses. A major
problem in genomic research is the high dimensional data, which can
increase the potential for false-positive results. This can be handled by
false detection rate (FDR) techniques or through test–retest approaches,
but our approach for dimension reduction is to explore the model of the
relationship between the exposures, in this case parity, and the out-
come, in this case breast cancer, in a large prospective study and then
perform strict hypothesis testing in the functional data. In the whole
NOWAC study, the mathematical model for the relationship between
parity and breast cancer were decided through statistical analyses that
included all women in the cohort [23]. The described 8% linear re-
duction per child based on an additive model was tested by in-
vestigating differences in blood gene expression between breast cancer
patients and controls in the postgenome biobank. The novel findings of
gene expression in relation to parity in these groups were unexpected.
Among controls, we found linear changes in the expression of hundreds
of genes for each child, while no changes were observed in women who were
later diagnosed with breast cancer.
The number of up-/downregulated genes for controls (FDR 5%) was
501/255 compared to the number of up/downregulated genes for
cases (FDR 5%) of 0/0.
Similar analyses of endometrial cancer showed the same relation-
ships with changes in gene expression following parity [24]. However,
for ovarian cancer no such relationship was found (data not shown).
Of the 10 most significant genes among controls, four were tumor
promotors, one was a tumor suppressor, and five were not known to be
related to carcinogenesis. It is worth repeating that the information on
function was mainly derived from studies of cancer tissues or reduc-
tionist experiments with small animals like mice and other rodents.
Locally, a tumor promotor appears to be important in tumor growth.
However, the interpretation of immune cells in the blood could be
different: it could imply that the organism has increased its gene ex-
pression as an alert, or there may be simply more immune cells as a
consequence of more memory cell clones. This view was supported by
analyses of the correlations between gene expression in the blood and
cancer tissue of women with breast cancer in the NOWAC study. After
gene clustering was performed, only tumors with high immunological
profiles showed a relationship with blood gene expression [21]. There
is a priori no reason to assume that immune cells in the blood should
mirror tumor tissue gene expression or that the functionality described
as relevant for immune cells in tissue studies would also be relevant in
blood due to highly different functions and biological material.
Proposing breast cancer as a pseudo semi-allograft
Breast tumor cells correspond to altered woman’s cells. The tumor is
obviously different from a fetus semi-allograft, and therefore is referred
to as a “pseudo” semi-allograft here. The cumulative incidence rates or
absolute risk among NOWAC participants with six children was half of
that of nulliparous women. From the immune system standpoint, one
could speculate that the immune effect was able to remove almost half
of potential tumors when moving from nulliparity to a parity of six.
Discussion
By inverting the traditional use of each full-term pregnancy as a
protective factor to the use of each deficient child as a risk factor, we
propose to change the paradigm of parity in epidemiology. In this new
paradigm, we were able to describe the importance of high parity in the
protection against postmenopausal breast cancer through analyses of
population-based studies. By shifting the focus from number of children
to full-term pregnancies, and by viewing the fetus as a semi-allograft,
we were able to document the linear relationship between full-term
pregnancies and breast cancer incidence. We were also able to observe
the relationship between full-term pregnancies and blood gene ex-
pression in women without breast cancer, while no such relationship
was found in breast cancer patients. The concept of the breast cancer as
a pseudo semi-allograft was a natural expansion of the theory. In breast
cancer, the pseudo semi-allograft may be “protected” by high levels of
hormones similar to those that protect the fetus during pregnancy,
demonstrating the dual effect of hormones. Clearly, breast cancer de-
velopment is opposed by the immune system in a dynamic balance over
time. Since the effect of childbirth on cancer risk could be confirmed
only for endometrial cancer and not for ovarian cancer it would be hard
to justify a more general theory for the carcinogenesis.
The interpretations of the breast cancer hypothesis have several
limitations. Due to lack of samples the analysis was run with all case-
control pairs under one hypothesis with no retest analysis as part of the
design. Dividing data into a test–retest design would reduce the power
of the hypothesis testing. In addition, the preservation method bof the
whole blood samples reduced the potential for a biological interpreta-
tion related to specific immune cell types.
The introduction of gene expression into the analysis of breast
cancer changed the context from just counting the number of children
to a more functional analysis, in which the relevant information on
parity includes the pregnancy-dependent changes and later changes in
immunology or biology. This is an important conceptual change.
Several methods could explain the observational findings. The
concept of immune surveillance is more than 60 years old. Today, it is
well accepted that parous women have functional, long-lived memory
cell clones and effector T cells that react against multiple tumor-asso-
ciated antigens (TAA), which are not found in nulliparous women. TAA-
specific Treg cells suppress strong effector T cell responses after birth
[25]. Specific T cell responses during pregnancy could be a product of
enhanced expression of shared pregnancy- and cancer-associated anti-
gens discovered in the breast tissue, placenta, and fetus. Lymphocytes
accumulate in pregnant women and develop in breast tissue simulta-
neously with increased expression of cancer-associated antigens, sup-
porting the hypothesis that pregnancy induces life-long immunization
against a variety of cancer-associated antigens.
A recent study of human immune cells after vaccination showed
that the long-term memory effects originate from CD8 T cells that di-
vided extensively after infection and some are maintained as quiescent
cells that last for decades with a very long doubling time [26].
Pregnancy is also associated with increased immune tolerance me-
chanisms, which prevent the mother’s immune system from reacting
against the fetus [27]. Cancer-specific memory T cells clones created by
fetal antigens in pregnant women might therefore be inhibited by T
regulatory cells in later breast cancer development. This could be one
mechanism behind the lack of relationship between blood gene ex-
pression and parity among women who develop breast cancer.
A population-based study showed that 25–50% of parous women
have detectable alloantibodies in their blood [28]. Although the
amount of antibodies against fetus HLA is an imprecise estimation of
total allo-immunization, it is obvious that there is a range in the quality
and quantity of pregnancy-induced immunization among women. This
might partly explain why some women do not obtain any pregnancy-
related advantages against breast cancer. However, there is a lack of
knowledge related to B cells, T cells, and especially the innate immune
system during and after pregnancy.
Another mechanism could be the fetal microchimerism, which is
defined as the long-term persistence of a few fetal-derived allogeneic
cells in the mother [29]. Each pregnancy could leave a clone of different
E. Lund et al. Medical Hypotheses 120 (2018) 76–80
79
fetal microchimerism cells.
A possible mechanism behind the protective effect of young age at
first pregnancy could be a longer duration of the immune protection
compared to women who are older at first pregnancy.
The concept of immune evasion could be part of the explanation of
the findings [30]. Immune evasion was considered as a hallmark of
cancer [31] covering many potential mechanisms.
Historically, before the Second World War, breast cancer was re-
ported to have been “cured” by violent spontaneous or intentionally
introduced infections. This link with the immune system was forgotten
for more than a half decade, but was recently reviewed [32].
This proposed theory that the biological memory of each pregnancy
lasts for decades is based on the existence of different memory T cell
clones created by the mother at the end of each full-term pregnancy.
Future studies should concentrate on an improved design for gene
expression related to the specific immune cells. Another important as-
pect would be the exploration of changes in the breast cells depending
on the number of pregnancies as indicators of a potential stem cell
mechanism. Through comparison between tumor tissue and normal
tissue the effects of intragenic mutations that promote or “drive” tu-
morigenesis [33] could be studied.
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